Global Xerostomia (Dry Mouth Disease) Therapeutics Market Size study & Forecast, by Type (Artificial Saliva/Saliva Substitutes, and Salivary Stimulants), Product (Drugs, Salivary Pens, and Other Product Types), Distribution Channel (Hospital Pharmacy, Ret

Global Xerostomia (Dry Mouth Disease) Therapeutics Market Size study & Forecast, by Type (Artificial Saliva/Saliva Substitutes, and Salivary Stimulants), Product (Drugs, Salivary Pens, and Other Product Types), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Regional Analysis, 2022-2029

Global Xerostomia (Dry Mouth Disease) Therapeutics Market is valued at approximately USD XXX billion in 2021 and is anticipated to grow with a healthy growth rate of more than 4.25% over the forecast period 2022-2029. A medical disorder known as dry mouth causes the mouth to become dry by affecting saliva production in the mouth. Body functions including eating, speaking, and digestion may be negatively impacted by this disorder. Malnutrition may result from this and have a harmful effect on the body. High dosage pharmaceuticals, antidepressants, hypnotics, anti-inflammatory meds, and other substances are the cause of these diseases. The market growth is supported by significant factors such as increasing adoption of chemotherapy and radiotherapy in cancer treatment, growing prevalence of diseases such as Sjogren’s Syndrome, HIV, diabetes, Alzheimer’s disease, and others and a growing geriatric population base.

The Centers for Disease Control and Prevention (CDC) estimate that each year, around 650,000 cancer patients get chemotherapy in an ambulatory oncology clinic. Additionally, a study named ""Artificial Saliva in Diabetic Xerostomia (ASDIX): Double Blind Trial of Aldiamed Versus Placebo"" that was released in July 2020 concluded that Aldiamed spray was superior to a placebo in treating xerostomia in people with type 1 and type 2 diabetes. These studies show that the use of artificial saliva replacements in the treatment of xerostomia is effective. However, the nonavailability of effective treatment stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Xerostomia (Dry Mouth Disease) Therapeutics Market study includes Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is leading the overall market share owing to the increasing prevalence of xerostomia and increase in HIV disease coupled with the increase in dry mouth awareness initiatives. However, Asia Pacific is expected to be the fastest growing region due to the rising prevalence of diseases such as diabetes and growing healthcare expenditure.

Major market players included in this report are:
Lupin Limited
Quest Products, Inc.
Parnell Pharmaceuticals, Inc.
Fresenius SE & Co. KGaA
Hikma Pharmaceuticals PLC
Sun Pharmaceutical Industries Ltd
GlaxoSmithKline PLC
ADVANZ PHARMA Corp. Limited
Pharmascience Inc
Synedgen, Inc.

Recent Developments in the Market:
In April 2021, Parnell Pharmaceuticals, Inc. launched the Mouth Kote-MD mouthwash based on MycoDelens, a proprietary substance created and licenced by New Mexico Tech University.
Virginia Head & Neck Therapeutics, Inc. introduced Voutia in February 2021, a medication that continuously relieves xerostomia (commonly known as chronic dry mouth). For the millions of people who experience this painful and frequently disabling illness, the unique, FDA-approved device provides a whole new strategy.

Global Xerostomia (Dry Mouth Disease) Therapeutics Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Type, Product, Distribution Channel, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World

The objective of the study is to define the market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study.

The report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with a detailed analysis of the competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:
By Product:
Artificial Saliva/Saliva Substitutes
Salivary Stimulants
By Type:
Drugs
Salivary Pens
Other Product Types
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Companies Mentioned

Lupin Limited
Quest Products, Inc.
Parnell Pharmaceuticals, Inc.
Fresenius SE & Co. KGaA
Hikma Pharmaceuticals PLC
Sun Pharmaceutical Industries Ltd
GlaxoSmithKline PLC
ADVANZ PHARMA Corp. Limited
Pharmascience Inc
Synedgen, Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.